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

	

To determine the longterm treatment effects beyond the two year followup reported 
in the PROFHER randomised clinical trial that compared surgery versus nonsurgical 
treatment of adults with displaced proximal humeral fractures involving the surgical 
neck. 

	
Trial participants consenting to the extended followup were sent postal 
questionnaires at three, four and five years after trial recruitment. The Oxford 
Shoulder Score (OSS; the primary outcome), EQ5D3L, and recent shoulder 
operations and fractures data were collected. Statistical and economic analyses, 
consistent with those of the main trial were applied. 


OSS data were available for 164, 155 and 149 participants at three, four and five 
years. There were no statistically or clinically significant differences between surgical 
and nonsurgical treatment at each followup in the OSS. No participant had 
secondary shoulder surgery for a new complication. Analyses of EQ5D data showed 
no significant betweengroup differences in quality of life over time. 

		
These results confirm that the main findings of the PROFHER trial over two years 
following fracture occurrence persist in the long term.








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	
 
This article reports on the extended followup, up to five years, of participants 
randomised into the PROximal Fracture of the Humerus Evaluation by Randomisation 
(PROFHER) trial. PROFHER was a pragmatic, multicentre randomised controlled 
trial (RCT), funded by the UK National Institute for Health Research ( NIHR), that 
compared surgical with nonsurgical treatment of adults with displaced fractures of 
the proximal humerus involving the surgical neck [1]. It recruited 250 adults between 
September 2008 and April 2011, with data available for the Oxford Shoulder Score 
(OSS)[2,3], the primary outcome, from 215 participants at two year followup.[4] The 
results for the main prespecified reporting period for PROFHER showed no 
significant difference between surgical treatment compared with nonsurgical 
treatment in the OSS and other patientreported clinical outcomes over two years 
following fracture [4,5] and that surgery cost significantly more over this period [6]. 
 
The initial choice of a two year followup for PROFHER was a pragmatic one that 
balanced feasibility and the expectation that any differences in the OSS between the 
two treatment groups by two year followup ould represent a true and enduring 
effect. However, there is insufficient evidence from other RCTs to confirm this 
assumption [7]. Recovery from serious injuries such as proximal humeral fractures is 
a long and often incomplete process that can be hindered by complications. A 
substantial proportion of participants of a trial with less severe fractures than in 
PROFHER had continuing disability at two years followup, although reduced from 
the proportion at one year.[8] We reasoned that a five year followup would allow for 
delays in recovery, potential functional deterioration, and subsequent operations 
resulting from complications, such as avascular necrosis and complications of surgical 
fixation or humeral head replacement, which could arise or become symptomatic later 
on.  The extension made sense practically as the infrastructure in place and the 
potential availability of a large group of patients – we anticipated there would be 200 
followed up at two years – presented an unprecedented opportunity to gain important 
insights and reliable evidence on patientreported longerterm outcome as well as 
insights on the feasibility of future research in this patient population. Hence, we set 
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up the extended followup study, securing ethics approval in September 2010 [5]; 
thus, prior to end of recruitment and without knowledge of the main study results.  
Our primary aim was to obtain three, four and five year data on key outcomes (OSS, 
EQ5D3L (EuroQol Group, Rotterdam, Netherlands [9]) and  subsequent surgery) in 
order to determine whether there was persistence or alteration of the treatment effect 
detected at two year followup, the definitive end point for the main trial. An 
associated aim, linked with the collection of EQ5D3L data and information on 
secondary surgery, was to examine the potential effects on our economic analysis [6] 
of any changes in quality of life and costs related to this key cost driver.  
 
Our secondary aims were to: 
 Obtain longer term condition specific data on shoulder function that would 
provide reference data for informing the interpretation of the findings of 
PROFHER and future studies of proximal humeral fractures. 
 
 Inform future research in this area on the appropriate duration of followup. 
 
	

Trial methods relating to the main study are reported elsewhere [1,5]. The trial 
inclusion and exclusion criteria are shown in Table 1. The trial protocol facilitated the 
implementation of good standards of treatment with the surgeons and physiotherapists 
using surgical interventions and procedures with which they were familiar. As 
reported, both interventions, including choice of surgical implants, and associated care 
programmes were representative of good current practice.[5] The final version of the 
extended study protocol (version 3.0; 09/08/12) is published on the NIHR website 
[10]; all related amendments were reviewed and approved by the Leeds West 
Research Ethics Committee (08/H1311/12). 
 


	

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Outcome collection for the extended followup comprised postal questionnaires sent 
at three, four and five years after trial recruitment to all participants who had 
completed and returned a consent form sent within receipt of their 24 month 
questionnaire. A prenotification letter was sent prior to the questionnaire and, where 
necessary, reminders were sent after two and four weeks, with the option to complete 
questionnaires via telephone after six weeks. To maximise collection of data at the 
three time points, patients were asked to complete a short questionnaire restricted to 
the OSS, EQ5D3L, recent operations on their shoulder, and recent fractures. Patients 
were also sent an unconditional £5 incentive payment with each questionnaire. We 
also collected data from the NHS Information Centre on patient mortality at regular 
intervals prior to dispatch of questionnaires; this was to prevent distressing bereaved 
families or friends.  
 

The primary outcome was the OSS, a shoulderspecific outcome assessing pain, 
function and activities of daily living.[2,3] It contains 12 items, each with 5 categories 
of response, and a range of total scores of 0 (worst outcome) to 48 (best outcome).[3] 
Secondary outcomes were the EQ5D3L, used to estimate utilities (‘health related 
quality of life weights’)[9], further shoulder surgery and further fractures. While 
mortality was a secondary outcome in the main followup, it was reported solely as a 
reason for loss to followup in the extended followup because mortality and 
definitive treatment of the fracture after two years could not reasonably be expected to 
be linked. The OSS and EQ5D3L were collected at 6, 12, 24, 36, 48 and 60 months; 
EQ5D3L data were also collected at baseline and three months. Secondary shoulder 
surgery and further fractures were collected via hospital forms at one and two years; 
and via patient questionnaires at three, four and five years followup. 

	
 
The main study was designed to detect a standard effect size of 0.4 (approximating to 
5 OSS points) with 80% power using 5% significance level, requiring approximately 
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200 participants (at 2 years)[1]. We considered that a 20% attrition rate at 5 years was 
a reasonable assumption to make for the population under study. We therefore based 
our proposal on a final sample size of 160 at the end of the five year followup period, 
which would provide 71% power to detect a standard effect size of 0.4 using 5% 
significance level. Given the reduced statistical power for the extended followup, 
significance testing was limited to the primary outcome alone. 

		

	

 
Analyses followed prespecified formal analysis plans, the statistical analysis plan 
also being endorsed by the Data Monitoring and Ethics Committee, and were 
performed using Stata version 13.1 (StataCorp). All analyses were on an intentionto
treat basis, with participants being analysed in the groups to which they were 
randomised. Significance tests were 2sided at the 5% significance level. 
 
	


OSS data from the extended followup time points were added to the PROFHER trial 
primary analysis model. The model compared OSS data from surgical and non
surgical treatment groups over all followup assessments. A multilevel model was 
fitted with time points nested in patients to allow for clustering of data within each 
patient. The model adjusted for the fixed effects of treatment group, time (6 months, 
1, 2, 3, 4 and 5 years), interaction between treatment group and time, tuberosity 
involvement at baseline (yes or no), age (less than 65 years, 65 years or older), gender 
and health status at baseline (EQ5D). The unstructured covariance pattern was 
retained from the primary analysis model. Patients with valid OSS data at one or more 
followup points for the standard or extended followup as well as complete covariate 
data were included in the analysis. Estimates of the difference in OSS between 
treatment groups, 95% confidence intervals and pvalues were obtained for the 
extended followup time points at three, four and five years. 
 
In a sensitivity analysis, the multilevel model was repeated substituting missing data 
with data derived by multiple imputation by chained equations. Missing outcome and 
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covariate data were imputed from age, gender, tuberosity involvement, EQ5D3L 
index at baseline and available OSS data at other followup points.  
	


In line with the main trial, the possibility of differential longterm treatment responses 
for older patients (subgroups: less than 65 years versus 65 years or older) and more 
complex fractures (subgroups: involvement of no tuberosities versus one or both 
tuberosities) was explored. Prior expectations of the benefit of surgery over 
conservative treatment, established before knowledge of the main trial results, were 
that this was larger in patients under 65 years and larger in patients with fractures 
involving one or both tuberosities [1], and that these benefits may only emerge in the 
longer term [10]. Unadjusted OSS means by subgroups and treatment arm were 
therefore explored. In light of the substantially reduced statistical power for the 
subgroups, no statistical testing was performed.  
 


Annual and overall frequencies of shoulder surgery and fractures in each treatment 
group occurring within the previous year were calculated. Extended followup data 
were combined with those of the main trial to establish the number of participants by 
treatment group incurring secondary shoulder surgery or a further fracture over five 
years. Free text providing details of further surgery and nonprespecified fractures 
was categorised, blind to treatment group, by two independent raters.   

	


The economic analysis aimed to explore whether the results obtained in the 
PROFHER trial were robust over a five year time horizon by determining the 
betweengroup differences in HealthRelated Quality of Life (HRQoL, measured via 
the EQ5D3L) at set times (3, 4 and 5 years) and examining how this difference 
evolved over time (5 years). We also planned to estimate costs of any further shoulder 
surgery and report these descriptively. 
The methods used to process the EQ5D3L data and calculate QALY (quality of life) 
scores were as in the main costeffectiveness report [6]. In summary, the EQ5D3L 
data were transformed into ‘health related quality of life weights’ (utilities) using the 
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UK general population tariff which assigns societal values to each health state [11].  
QALYs were calculated by combining the utility estimates by the duration of time in 
each health state using the area under the curve method (AUC) following the 
trapezium rule which assumed linear interpolation between followup points [12]. A 
discount rate was applied to QALYs after 12 months, at an annual rate of 3.5% [13].  
In the main trial, the basecase analysis was conducted for the imputed dataset by 
means of multiple imputation (MI) with chained equations, using seemingly unrelated 
regression [6]. This method accounts for the correlation between costs and effects 
from the same individuals and imputes the missing data.  However, other regression
based methods are available for handling missing data in longitudinal studies, 
principally mixed models, and results may be sensitive to the methods used [14]. A 
multilevel model similar to the primary OSS analysis was therefore conducted to 
investigate whether the results obtained in the main trial were robust to this alternative 
method of analysis. Thus the mean difference in utilities and QALYs (with 95% 
confidence intervals) between the two groups was estimated using a multilevel model 
that adjusted for the fixed effects of treatment group, time (3 and 6 months, 1, 2, 3, 4 
and 5 years), interaction between treatment group and time, tuberosity involvement at 
baseline, age, gender and baseline utility.  
Uncertainty around the results was explored by means of sensitivity analysis that used 
multiple imputation by chained equations to replace missing data on QALYs in the 
multilevel model where missing outcome and covariate data were imputed from age, 
gender, tuberosity involvement, and baseline utility.  
 
 


Of 176 patients (81% of the 218 who returned questionnaires at two years; 70% of 
250 randomised trial participants) who consented to long term followup at two years 
following randomisation, valid Oxford Shoulder Scores (OSS) were received for 164 
(93%) at three years, 155 (88%) at four years, and 149 (85%) at five years followup 
(Figure 1). Retention was therefore slightly lower than anticipated in the extended 
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followup; however, additional power was gained by the multilevel analysis. Ten 
patients died during the long term followup, five in each trial arm.
As found at baseline (except for smoking status, which did not affect the OSS results) 
and two year followup [4], patient characteristics were balanced between groups at 
five year followup in the 149 patients with complete OSS data (Tables IIa and b). 
Furthermore, the characteristics of the RCT population remained representative, as 
none of the baseline characteristics differed meaningfully between participants at the 
start of the trial and those remaining at the end.  
	
Unadjusted OSS outcomes for patients with valid data were very similar in both 
groups for the extended followup period (Figure II). This featured a trend of small 
score increases between two and four years, with little difference in the fifth year. 
OSS scores were skewed towards maximum OSS shoulder functioning, with over half 
the population having stable and satisfactory shoulder function [3] at all three follow
up times: three years (median 42, IQR 35 to 47.5); four years (median 43, IQR 37 to 
48); five years (median 44, IQR 36 to 48). 
When adding the long term OSS followup data to the existing multilevel analysis, 
group differences were not statistically significant at any of the long term followup 
time points. This was true for the primary analysis model including all patients with 
available outcome data at any time point as well as the se sitivity analysis including 
all patients using data derived by multiple imputation (Table III and Table IV). None 
of the estimated mean differences were clinically meaningful; almost all were smaller 
than one OSS score point in magnitude with no consistent trend for the direction of 
the treatment effect. 
The substantial overlap of the confidence intervals for the unadjusted OSS scores 
indicated there were no marked treatment group differences for patient subgroups 
based on age (Figure III) or tuberosity involvement (Figure IV). In both subgroups, 
the patterns of OSS score differences were not consistent with prior expectations. 


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Only one patient reported further shoulder surgery during extended followup. This 
was a reverse shoulder replacement in year three in a nonsurgical group patient who 
already had surgery in the main followup. Thus the number of participants requiring 
secondary surgery remained at 11 in each treatment group [4]. 
A total of 81 further fractures were reported by 52 patients over the five year follow
up period. A small number of fractures are likely to be duplicated from one year to the 
next; however, as this could not be known definitively, patient data were accepted as 
submitted, with the exception of one participant who provided the date of their 
fracture. There were more fractures in the nonsurgery group (50 fractures, 33 
patients) than the surgery group (31 fractures, 19 patients); in particular, fractures of 
the spine and hip (Table V). 

	

Inevitably, relative to the 125 randomised into each treatment group, the extent of 
missing EQ5D3L data increased considerably in the extended followup period. For 
the 176 participants that consented to long term followup, complete EQ5D3L 
scores were available for 159 (90%) at three years, 153 (86%) at four years and 151 
(86%) at 5 years.  
 
Figure V shows the distribution of mean utilities (EQ5D3L scores) for all the 
available cases across the five years for the two groups. Patients in the surgery group 
started from a higher baseline utility on average (0.43, surgery 

 0.38, not 
surgery). However, at the end of the second year there was little difference in EQ5D
3L scores between treatment groups. This finding was consistent at three, four and 
five years with the 95% confidence intervals overlapping at each assessment point.  
The same pattern applied for the analysis of utilities when adjusted for baseline utility 
or for all covariates (Table VI).  
Between group mean difference in QALYs based on individual patient’s utilities are 
shown in Table VII. At the end of the five years, patients allocated to the not surgery 
group obtained on average a marginally higher QALY gain than patients allocated to 
the surgery group. Hence the QALY gain for not surgery patients is maintained over 
time whether data are adjusted for baseline utility or for all covariates. The mixed 
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model, which included 200 cases, was repeated substituting missing data with data 
derived by multiple imputation by chained equations. For both analyses, there were 
negligible differences in the QALYs between the two groups at the different follow
up times (Table VII).  

		
 
The extension of followup has found no statistically or clinically significant 
differences between surgical and nonsurgical treatment of displaced fractures of the 
proximal humerus involving the surgical neck at three, four or five years in the OSS, 
our primary outcome. Visual inspection of two subgroup analyses did not suggest any 
trend for group differences relating to age or fracture type. These findings mirror 
those of the main trial. No trial participant had secondary shoulder surgery for new 
complication during the extended followup period. The between group differences in 
utilities, based on EQ5D3L data, at three, four or five years were very small with the 
95% confidence intervals overlapping at each assessment point. The same lack of 
statistically significant betweengroup differences applied to the quality of life 
analysis that showed the trend for a QALY gain for participants in the not surgery 
group is maintained over time. Sensitivity analyses indicated minimal differences 
between the two groups at each followup time.  
 
By exceeding the original target of 200 participants at two year followup, PROFHER 
was sufficiently powered at the main followup. In contrast, we were 11 short of the 
160 participants with OSS data at five years, and thus did not meet the revised 
statistical power criteria for the extended followup. However, we believe this is 
unlikely to affect the validity of the results. First, losstofollowup including identical 
mortality (5 in each group) was balanced in both groups. Second, baseline 
characteristics at five years were comparable between groups as well as being 
representative of the original population. Third, much of the missing data was 
accounted for in the multilevel analysis, which included 231 cases. Fourth, the 
between group differences were small with the 95% confidence intervals at each 
followup time less than the minimal clinically important difference of 5 points. Fifth, 
the between group differences in the EQ5D3L were also very small, again reflecting 
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comparability of the groups. Last, there were no new complications warranting 
surgery.  
 
Although there were no cost data to replicate the incremental costeffectiveness 
analysis conducted for the PROFHER trial, the analyses of the health utility data for 
the five year period produced results that are consistent with the main trial analysis; 
on average, patients allocated to surgery reported lower HRQoL. The very small 
differences in HRQoL between the two groups found for the mixed model and 
multiple imputation analyses indicate negligible differences in quality of life between 
the treatment groups. The costs of the only shoulder operation reported for the 
extended followup would not have impacted on the findings of the main trial. 
 
We consider that it is unsafe to draw any conclusions from the observed differences in 
participants incurring further fractures between the two groups in relation to treatment 
group allocation. We suggest this is primarily a chance effect. In terms of known risk 
factors for fractures (such as higher age, female gender, previous fracture and 
smoking), the two groups were at similar risk of further fractures at baseline except 
for smoking status, where there was a higher incidence of smokers in the not surgery 
group. This may partly explain a higher number of fractures in that group. Known 
inaccuracies, relating to both under and overreporting, of selfreported fractures are 
of some concern and indeed, based on additional participant commentary, we 
confirmed one instance of duplicate reporting over time. We also have no information 
on whether there was any difference in the advice offered and medication provided for 
preventing further fractures in the two groups.  
 
Our findings of an absence of treatment differences in the OSS in the extended 
followup underpin the main findings for the two year followup. The only case of 
further surgery over the extended followup was repeat surgery for a complication that 
occurred within the two year followup. Given that most (15 of 22) secondary surgery 
occurred in the first year, this finding and the lack of difference in the OSS provide 
reassurance that late symptomatic complications are rare. The healthrelated quality of 
life results show that the PROFHER economic analysis persisted over a five year time 
horizon. The overall OSS results show that the majority of patients have attained 
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satisfactory shoulder function by two years, which is sustained subsequently. Thus the 
two year followup would have been sufficient for the PROFHER trial, and this could 
inform followup for future RCTs on these fractures. 



We are grateful to the patients who generously completed questionnaires for the 
extended followup. We thank ….  and …. for checking the Summary Care Records 
of patients for mortality, and staff at various participating sites for their help in 
locating missing patients.  
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Inclusion and exclusion criteria of the PROFHER trial 

				
			
 Adults (aged 16 or above) presenting within three weeks of their injury with a 
radiologically confirmed displaced fracture of the humerus involving the 
surgical neck. This should include all two part surgical neck fractures; three 
part (including surgical neck) and four part fractures of proximal humerus 
(Neer Classification).911 It may also include displaced surgical neck 
fractures that do not meet the exact displacement criteria of the Neer 
Classification (1 cm or/and 45° angulation of displaced parts) where this 
reflects an individual surgeon’s uncertainty (e.g., whether or not the surgical 
neck fracture should be treated surgically). 
 
			
 Associated dislocation of the injured joint of the shoulder 
 Open fracture 
 Mentally incompetent patient: unable to understand trial procedure or 
instructions for rehabilitation; significant mental impairment that would 
preclude compliance with rehabilitation and treatment advice 
 Comorbidities precluding surgery/anaesthesia 
 A clear indication for surgery such as severe softtissue compromise requiring 
surgery/emergency treatment (nerve injury/dysfunction) 
 Multiple injuries: same limb fractures; other upper limb fractures 
 Pathological fractures (other than osteoporotic) and terminal illness 
 Participant not resident in catchment area of trauma centre 
 
 
 

Baseline characteristics (demographics) at randomisation and five years 
followup 

 
	
 !"	
		##
$%
&		 #%
'()*+$,
(
#%
'()*+$,
#%
'()-.,
(
#%
'()-/,
0     
  Male, n (%) 28 (22.4) 30 (24.0) 19 (25.0) 15 (20.6) 
  Female, n (%) 97 (77.6) 95 (76.0) 57 (75.0) 58 (79.5) 
'%,     
  Mean (SD) 66.60 
(11.80) 
65.43 
(12.09) 
65.80 
(10.12) 
65.33 
(11.35) 
  Median (min, max) 67.42  
(27.04, 
66.12  
(24.63, 
65.69 
(37.09, 
65.37 
(31.33, 
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 
	
 !"	
		##
$%
&		 #%
'()*+$,
(
#%
'()*+$,
#%
'()-.,
(
#%
'()-/,
92.04) 89.02) 87.76) 84.56) 
'",     
  Less than 65 years, n (%) 51 (40.8) 57 (45.6) 34 (44.7) 36 (49.3) 
Equal or greater than 65 years, n 
(%) 
74 (59.2) 68 (54.4) 42 (55.3) 37 (50.7) 
		%      
  White, n (%) 124 (99.2) 125 
(100.0) 
75 (98.7) 73 (100.0) 
  Black, n (%) 1 (0.8) 0 (0.0) 1 (1.3) 0 (0.0) 
	     
No formal qualifications, n (%) 66 (52.8) 68 (54.4) 35 (46.1) 35 (48.0) 
Some qualifications but no 
degree, n (%) 
47 (37.6) 43 (34.4) 34 (44.7) 25 (34.3) 
  Degree or higher, n (%) 12 (9.6) 14 (11.2) 7 (9.2) 13 (17.8) 

"%
     
  Parttime, n (%) 12 (9.6) 7 (5.6) 10 (13.2) 5 (6.9) 
  Fulltime, n (%) 17 (13.6) 22 (17.6) 12 (15.8) 15 (20.6) 
  Selfemployed, n (%) 1 (0.8) 3 (22.4) 0 (0.0) 3 (4.1) 
  Retired, n (%) 78 (62.4) 82 (65.6) 43 (56.6) 45 (61.6) 
Not employed but seeking work, 
n (%) 
3 (2.4) 1 (0.8) 2 (2.6) 1 (1.4) 
  Other, n (%) 12 (9.6) 9 (7.2) 9 (11.8) 3 (4.1) 
  Missing, n (%) 2 (1.6) 1 (0.8) 0 (0.0) 1 (0.7) 
	     
  Yes, n (%) 18 (14.4) 13 (10.4) 8 (10.5) 8 (11.0) 
  No, n (%) 106 (84.8) 111 (88.8) 67 (88.2) 64 (87.7) 
  Missing, n (%) 1 (0.8) 1 (0.8) 1 (1.3) 1 (1.4) 
#
	     
  Yes, n (%) 24 (19.2) 40 (32.0) 13 (17.1) 16 (21.9) 
  No, n (%) 96 (76.8) 81 (64.8) 61 (80.3) 55 (75.3) 
  Missing, n (%) 5 (4.0) 4 (3.2) 2 (2.6) 2 (2.7) 
#	     
  Yes, n (%) 6 (4.8) 7 (5.6) 4 (5.3) 6 (6.9) 
  No, n (%) 118 (94.4) 116 (92.8) 72 (94.7) 67 (91.8) 
  Missing, n (%) 1 (0.8) 2 (1.6) 0 (0.0) 1 (1.4) 
!#'12$,     
Page 16 of 26
https://mc04.manuscriptcentral.com/bjj
The Bone & Joint Journal
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review Only
17 
 
 
	
 !"	
		##
$%
&		 #%
'()*+$,
(
#%
'()*+$,
#%
'()-.,
(
#%
'()-/,
  N 123 121 75 70 
  Mean (SD) 0.43 
(0.37) 
0.38 
(0.37) 
0.43 
(0.36) 
0.34 
(0.36) 
  Median (min, max) 0.59 (
0.36,1) 
0.26 (
0.35,1)
 
0.59 (
0.35, 1) 
0.24 (
0.35, 1) 


Baseline characteristics (fracture data) at randomisation and five years 
followup 
 
 
	
 !"	
		##
$%
&		 #%
'()*+$,
(
%
'()*+$,
#%
'()-.,
(
%
'()-/,
	
		3%'%,    
  Mean (SD) 5.78 
(4.90) 
5.69 
(4.89) 
5.93 
(5.17) 
5.82 
(4.59) 
  Median (min, max) 4 (0, 19) 4 (0, 21) 4.5 (0, 19) 4 (0, 18) 
     
  Left, n (%) 57 (45.6) 68 (54.4) 32 (42.1) 40 (54.8) 
  Right, n (%) 68 (54.4) 57 (45.6) 44 (57.9) 33 (45.2) 
	%	44
     
  Yes, n (%) 99 (79.2) 94 (75.2) 58 (76.3) 58 (79.5) 
  No, n (%) 26 (20.8) 31 (24.8) 18 (23.7) 15 (20.6) 
	%	44
'	,     
Tuberosity not involved or 
missing, n (%) 
26 (20.8) 31 (24.8) 18 (23.7) 15 (20.6) 
  Greater tuberosity, n (%) 58 (46.4) 61 (48.8) 34 (44.7) 36 (49.3) 
  Lesser tuberosity, n (%) 7 (5.6) 3 (2.4) 4 (5.3) 1 (1.4) 
Greater and lesser tuberosity, n 
(%) 
34 (20.8) 30 (24.0) 20 (26.3) 21 (28.8) 
 	"*5%     
  Yes, n (%) 33 (26.4) 33 (26.4) 19 (25.0) 19 (26.0) 
  No, n (%) 92 (73.6) 90 (72.0) 57 (75.0) 53 (72.6) 
  Missing, n (%) 0 (0.0) 2 (1.6) 0 (0.0) 1 (1.4) 
4	%     
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 
	
 !"	
		##
$%
&		 #%
'()*+$,
(
%
'()*+$,
#%
'()-.,
(
%
'()-/,
  Yes, n (%) 8 (6.4) 12 (9.6) 3 (4.0) 9 (12.3) 
  No, n (%) 23 (18.4) 21 (16.8) 14 (18.4) 10 (13.7) 
  Missing, n (%) 2 (1.6) 0 (0.0) 2 (2.6) 0 (0.0) 
  No previous fractures, n (%) 92 (73.6) 92 (73.6) 57 (75.0) 54 (74.0) 
#
		     
  Yes, n (%) 67 (53.6) 61 (48.8) 40 (52.6) 36 (49.3) 
  No, n (%) 56 (44.8) 62 (49.6) 34 (44.7) 35 (48.0) 
  Missing, n (%) 2 (1.6) 2 (1.6) 2 (2.6) 2 (2.7) 
3%
	
     
Fall or trip from standing height 
or less, n (%) 
90 (72.0) 96 (76.8) 55 (72.4) 58 (79.5) 
Fall downstairs/steps or from a 
height, n (%) 
18 (14.4) 17 (13.6) 11 (14.5) 9 (12.3) 
  Other, n (%) 15 (12.2) 9 (7.2) 8 (10.5) 5 (6.9) 
  Missing, n (%) 2 (1.6) 3 (2.4) 2 (2.6) 1 (1.4) 
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
Difference in mean OSS over time by treatment group; extended primary 
analysis model
* 
 
 #%
'6$7&,
(%
'6$7&,
	
'6$7&,
"2
4
No. 
patients
†‡
 
114 117 231  
6 
months
‡
 
37.84 (35.93, 39.65) 35.59 (33.62 to 
37.45) 
2.25 (0.07 to 4.57) 0.058 
1 year
‡
 39.23 (37.38, 40.99) 38.80 (36.99 to 
40.53) 
0.42 (1.78 to 2.63) 0.706 
2 years
‡
 40.11 (38.24, 41.90) 40.40 (38.59 to 
42.13) 
0.29 (2.53 to 
1.95) 
0.800 
No. 
patients
†
 
114 117 231  
3 years 40.53 (38.73 to 
42.25)  
40.36 (38.58 to 
42.06) 
0.17 (2.02 to 2.35) 0.880 
4 years 40.87 (39.04 to 
42.62) 
41.45 (39.67 to 
43.16) 
0.58 (2.81 to 
1.64) 
0.607 
5 years 40.89 (39.99 to 
42.70) 
41.98 (40.14 to 
43.74) 
1.09 (3.41 to 
1.23) 
0.356 
*
 
Multilevel model of Oxford Shoulder Score (OSS, score range 0 to 48, higher scores indicate better 
outcomes) adjusted for treatment group, time (6, 12, 24, 36, 48 and 60 months), group × time 
interaction, baseline EQ5D index, gender, age group (< 65 years/≥ 65 years) and tuberosity 
involvement at baseline (yes/no) 
† 
Number of patients included in the analyses (complete baseline characteristics and valid OSS score 
for at least one followup, same for primary and longterm analyses)  
‡ 
Rows obtained from original ProFHER trial analysis 

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 8Difference in mean OSS over time by treatment group; data derived by 
multiple imputation
*
 
 #%
'6$7&,
(%
'6$7&,
	
'6$7&,
"2
4
No. 
patients
†
 
125 125 250  
6 
months
†
 
37.96 (36.07 to 
39.76) 
35.67 (33.71 to 
37.54) 
2.28 (0.04 to 4.61) 0.054 
1 year
†
 39.29 (37.48 to 
41.03) 
38.84 (37.03 to 
40.56) 
0.46 (1.72 to 2.64) 0.680 
2 years
†
 40.18 (38.36 to 
41.93) 
40.54 (38.72 to 
42.28) 
0.36 (2.58 to 
1.87) 
0.752 
No. 
patients 
125 125 250  
3 years 40.59 (38.79 to 
42.31) 
40.22 (38.46 to 
41.91) 
0.36 (1.86 to 2.58) 0.748 
4 years 40.97 (39.14 to 
42.71) 
41.52 (39.84 to 
43.13) 
0.55 (5.64 to 
1.53) 
0.602 
5 years 40.96 (39.10 to 
42.75) 
41.90 (40.13 to 
43.59) 
0.93 (3.19 to 
1.32) 
0.416 
* Missing OSS and covariate data derived by multiple imputation. Multilevel model adjusted for 
treatment group, time (6, 12, 24, 36, 48 and 60 months), group × time interaction, baseline EQ5D 
index, gender, age group (< 65 years/≥ 65 years) and tuberosity involvement at baseline (yes/no) 
† 
Rows obtained from original ProFHER trial analysis 

8Further fractures by treatment arm 
 #% (% 
 M0
24* 
M24
60
†
 
Total 
 
M0
24 
M24
60 
Total 
 
M0
24 
M24
60 
Total 
 N N N N N N N N N 
Shoulder/ 
upper arm 
1 5 6 2 4 6 3 9 12 
Wrist 3 6 9 5 7 12 8 13 21 
Hip 3 1 4 7 2 9 10 3 13 
Spine 1 0 1 1 10 11 2 10 12 
Elbow 0 0 0 1 2 3 1 2 3 
Ankle 2 1 3 0 1 1 2 2 4 
Other 0 8 8 2 6 8 2 14 16 
Total 
fractures 
10 21 31 18 32 50 28 53 81 
Total 
patients 
10 12 19 15 21 33 25 33 52 
* M024: Followup up to 2 years; 
† 
M2460: Extended followup from 2 to 5 years 
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8 Difference in mean EQ5D3L over time by treatment group derived by 
multilevel model*

#%
',
(#%
',
	'6$7&,
'#%2(#%,
No. patients 123 121 244 
3m 0.61 (0.03) 0.60 (0.03)  0.01 ( 0.06 to 0.08) 
6m 0.66 (0.03) 0.63 (0.03)  0.03 ( 0.04 to 0.10) 
12 m 0.63 (0.03) 0.66 (0.03) 0.02 ( 0.09 to 0.05) 
2 years 0.66 (0.03) 0.66 (0.03) 0.00 (0.08 to 0.07) 
3 years 0.65 (0.03) 0.63 (0.03)  0.02 (0.06 to 0.10) 
4 years 0.67 (0.03) 0.62 (0.04)  0.05 (0.04 to 0.14) 
5 years 0.65 (0.04) 0.62 (0.04)  0.03 (0.07 to 0.13) 
*Multilevel model for EQ5D3L (score range 0 to 1, higher scores indicate better HRQoL) adjusted 
for treatment allocation,  time (3, 6,12, 24, 36, 48 and 60 months), grouptime interaction, baseline EQ
5D3L index, gender, age group and tuberosity involvement at baseline (yes/no). Number of patients 
included in the analyses (complete baselines characteristics and EQ5D score for at least one follow
up).  


8HRQoL: Mixed model and multiple imputation sensitivity analyses at 
each followup time up to five years
 2" 	
9

	1:;
'34	,
'#%2(%,
'6$7&,
'()+55,
 †

	"	
"	99

	1:;
'34	,
'#%2(%,
'6$7&,
'()+$5,
 
/
 0.001 (0.02 to 0.02) 0.002 (0.03 to 0.02) 
.
 0.028 (0.03 to 0.04)  0.000 (0.03 to 0.03) 
*% 0.004 (0.06 to 0.05) 0.004 (0.06 to 0.05) 
+% 0.031 (0.15 to 0.09) 0.024 (0.15 to 0.10) 
/% 0.061 (0.25 to 0.12) 0.034 (0.23 to 0.16) 
<% 0.063 (0.32 to 0.19) 0.027 (0.29 to 0.24) 
$% 0.042 (0.36 to 0.28) 0.013 (0.35 to 0.32) 
* Multilevel model for QALYs adjusted for treatment allocation, time (3,6,12, 24, 36, 48 and 60 
months), grouptime interaction, baseline utility, gender, age group and tuberosity involvement at 
baseline (yes/no).  
** Missing EQ5D and covariate data derived by multiple imputation. Multilevel model adjusted for 
treatment group, time (6, 12, 24, 36, 48 and 60 months), group × time interaction, baseline utility, 
gender, age group (< 65 years/≥ 65 years) and tuberosity involvement at baseline (yes/no) 
† 
Number of patients included in the analyses (complete baselines characteristics and QALYs score for 
at least one followup): 106 surgery; 94 not surgery 
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